KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Income (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Net Income for 7 consecutive years, with $210.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 14174.54% year-over-year to $210.8 million, compared with a TTM value of $287.2 million through Dec 2025, up 4893.08%, and an annual FY2025 reading of $287.2 million, up 4893.08% over the prior year.
  • Net Income was $210.8 million for Q4 2025 at Aurinia Pharmaceuticals, up from $31.5 million in the prior quarter.
  • Across five years, Net Income topped out at $210.8 million in Q4 2025 and bottomed at -$50.4 million in Q1 2021.
  • Average Net Income over 5 years is -$3.7 million, with a median of -$12.5 million recorded in 2023.
  • The sharpest move saw Net Income crashed 93.99% in 2021, then soared 14174.54% in 2025.
  • Year by year, Net Income stood at -$33.3 million in 2021, then grew by 21.92% to -$26.0 million in 2022, then dropped by 3.29% to -$26.9 million in 2023, then surged by 105.5% to $1.5 million in 2024, then skyrocketed by 14174.54% to $210.8 million in 2025.
  • Business Quant data shows Net Income for AUPH at $210.8 million in Q4 2025, $31.5 million in Q3 2025, and $21.6 million in Q2 2025.